CONMED (CNMD)
(Delayed Data from NYSE)
$71.76 USD
+1.64 (2.34%)
Updated May 3, 2024 04:00 PM ET
After-Market: $71.74 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CNMD 71.76 +1.64(2.34%)
Will CNMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CNMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNMD
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
Conmed (CNMD) Reports Q1 Earnings: What Key Metrics Have to Say
CNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Smith+Nephew (SNN) Expands in Australia With New Alliance
Here's Why You Should Retain CONMED (CNMD) Stock for Now
Other News for CNMD
$1M Bet On Skyworks Solutions? Check Out These 3 Stocks Insiders Are Buying
Insider Buying Alert: COO Pat Beyer Acquires Shares of Conmed Corp (CNMD)
CONMED Corporation to Present at the BofA Securities Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Conmed (CNMD) and BioMarin Pharmaceutical (BMRN)
Piper Sandler Sticks to Their Buy Rating for Conmed (CNMD)